Floatz logo

Gdc-0449

Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

National Cancer Institute (NCI)Phase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor cohort.

Asset / SponsorPhaseRating
Cixutumumab
National Cancer Institute (NCI)
Phase 2BB
Irinotecan
Gradalis, Inc.
Phase 3BB
Irinotecan
Gradalis, Inc.
Phase 3BB
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
FILGRASTIM
M.D. Anderson Cancer Center
Phase 2B

View all 36 →

Same molecule, other indications

Gdc-0449 is also rated in:

exocrine pancreatic carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
malignant pancreatic neoplasmDormant
BB
Indicative ·
65 / 100
View asset →
adult glioblastomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →